IP Library Granted Patent US 11,439,618
Granted Patent B2
US 11,439,618 · App. 17/148,449 · Granted Sep 13, 2022

Compositions and methods for lowering triglycerides

Inventors: Ian Osterloh (Kent, GB); Pierre Wicker (Mystic, CT); Rene Braeckman (Richboro, PA); Paresh Soni (Mystic, CT); Mehar Manku (Birmingham, GB)
Assignee: Amarin Pharmaceuticals Ireland Limited
A61K31/232A61K9/48A61K31/202A61K31/366A61K31/40A61K31/505A61P3/06A61P9/10C07C57/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,439,618
App. No.
17/148,449
Granted
Sep 13, 2022
Kind
B2
Abstract

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Claims (7)

1. A method of lowering triglycerides in a subject on stable statin therapy having type 2 diabetes mellitus and fasting triglycerides of about 200 mg/dl to about 500 mg/dl, the method comprising administering to the subject a composition comprising about 4 g of ethyl eicosapentaenoate per day for a period of time effective to reduce the fasting triglycerides in the subject wherein the composition comprises at least 96% by weight ethyl eicosapentanoate.

2. The method of claim 1 , wherein the subject has serum LDL-C levels of about 40 mg/dl to about 115 mg/dl.

3. The method of claim 1 , wherein the composition is administered to the subject 1 to 4 times per day.

4. The method of claim 3 , wherein the composition is present in one or more capsules.

5. The method of claim 1 , wherein the composition contains not more than about 10% by weight of docosahexaenoic acid or derivatives thereof.

6. The method of claim 1 , wherein the period is about 1 week to about 12 weeks.

7. The method of claim 1 , wherein the period is about 12 weeks.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2026
From: AMARIN PHARMA, INC.
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 074091/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2026
From: OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH; MANKU, MEHAR
To: AMARIN PHARMA, INC.
Reel/Frame 074071/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2021
From: OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH; MANKU, MEHAR; AMARIN PHARMA, INC.
To: AMARIN PHARMA, INC.; AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 055707/0615 →